























































Information from the CSAT Buprenorphine Information Center on the criteria required to receive waiver under DATA 2000.

- [Schedule of Opioids](#)  
A table showing the schedule of opioids.
- [The ASAM National Practice Guideline \(Medication Assisted Treatment\)](#)  
This document outlines the 2015 guidelines for assessment and pharmacological treatment of patients with opioid use disorder.
- [VIDEO: Patient Mike's Story](#)  
View three short webisodes that share Mike's buprenorphine success story. This story was taken from The National Alliance of Advocates for Buprenorphine Treatment (NAABT.org). Mike is an average middle-class American, a business owner, and a loving husband, father, and grandfather. While remodeling his restaurant, he hurt himself, and slowly became addicted to prescription opioid painkillers. A medication called buprenorphine, in addition to counseling and support, would allow him to get back on a productive path.
- [XR-Naltrexone: A Step-by-Step Guide](#)  
This step-by-step guide provides medical professionals a clear clinical plan from patient history intake to follow-up visit after administering XR-Naltrexone injections.

## REFERENCES USED IN THIS MODULE:

1. Substance Abuse and Mental Health Services Administration. [Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings](#). September 2014.
2. 21 USC § 812. [Schedules of controlled substances](#). 2012.
3. FSMB. [Model Policy on DATA 2000 and Treatment of Opioid Addiction in the Medical Office](#). *FSMB Website*. 2013.
4. Dowell D, Haegerich TM, Chou R. *CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016*. *MMWR Recomm Rep*. 2016;65(1):1-49. doi:10.15585/mmwr.rr6501e1er.
5. SAMHSA. [Key Substance Use and Mental Health Indicators in the United States: Results from the 2016 National Survey on Drug Use and Health](#). *SAMHSA.gov*. 2017.
6. National Center for Complementary and Integrative Health. [NIH Analysis Shows Americans are in Pain](#). *Natl Inst Health*. 2015.
7. CDC. [Opioid Data Analysis | Drug Overdose | CDC Injury Center](#). *Cent Dis Control Prev*. 2016.
8. CDC. [Understanding the epidemic](#). *Cent Dis Control Prev Natl Cent Inj Prev Control Div Unintentional Inj Prev*. 2017.
9. CDC. [Vital Signs: Overdoses of Prescription Opioid Pain Relievers - United States, 1999-2008](#). *MMWR*. 2011;60(43):1487-1492.
10. Warner M, Hedegaard H, Chen LH. [Trends in drug-poisoning deaths involving opioid analgesics and heroin: United States, 1999-2012](#). 2014.
11. SAMHSA. [Physician and Program Data](#). *SAMHSA.gov*. 2018.
12. ASAM. [The ASAM National Practice Guideline For the Use of Medications in the Treatment of Addiction Involving Opioid Use](#). June 1, 2015.
13. SAMHSA. [Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update](#). Winter 2016.
14. SAMHSA. [Methadone](#). *SAMHSA.gov*. 2015.
15. Office of National Drug Control Policy. [Medication-Assisted Treatment for Opioid Addiction](#). 2012.

16. Substance Abuse and Mental Health Services Administration (US), Office of the Surgeon General (US). [Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health](#). Washington (DC): US Department of Health and Human Services. 2016.
17. Renner J, Saxon A, Levounis P. [Buprenorphine Update and Evolving Standards of Care](#). IPS: The Mental Health Services Conference. October 2015. New York City.
18. Kissin W, McLeod C, Sonnefeld J, et al. *Experiences of a National Sample of Qualified Addiction Specialists Who Have and Have Not Prescribed Buprenorphine for Opioid Dependence*. *J Addict Dis*. 2006;25(4):91-103.
19. Alford DP, Labelle CT, Kretsch N, et al. *Collaborative Care of Opioid-Addicted Patients in Primary Care Using Buprenorphine: Five-Year Experience*. *Arch Intern Med*. 2011;171(5):425-431.
20. Arfken CL, Johanson CE, di Menza S, et al. *Expanding Treatment Capacity for Opioid Dependence with Office-Based Treatment with Buprenorphine: National Surveys of Physicians*. *J Subst Abuse Treat*. 2010;39(2):96-104.
21. Mintzer IL, Eisenberg M, Terra M, et al. *Treating Opioid Addiction with Buprenorphine-Naloxone in Community-Based Primary Care Settings*. *Ann Fam Med*. 2007;5(2):146-150.
22. FDA. [FDA approves first buprenorphine implant for treatment of opioid dependence](#). *FDA News Events*. May 26, 2016.
23. FDA. [FDA approves first once-monthly buprenorphine injection, a medication-assisted treatment option for opioid use disorder](#). November 30, 2017.
24. Mattick RP, Breen C, Kimber J. [Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence](#). *Cochrane Libr*. 2014.
25. ASAM. [Summary of the Comprehensive Addiction and Recovery Act](#). 2016.
26. Borg L, Kreek MJ. [The pharmacology of opioids](#). In: *In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, Eds. Principles of Addiction Medicine*. Vol 3. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine; 2003.
27. Lee JD, Friedmann PD, Kinlock TW, et al. *Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders*. *N Engl J Med*. 2016;374:1232-1242.
28. Volkow N. NIDA-supported science leads to first FDA-approved medication for opioid withdrawal. *NIDA*. 2018.
29. PCSS. [Vivitrol: How important is this piece of the treatment puzzle?](#). 2015.
30. PCSS. [XR-Naltrexone: A step-by-step guide](#). 2017.
31. U.S. Census Bureau. [2012 Statistical Abstract of the United States](#). *Census.gov*. 2012.
32. Madras BK, Wilson MC, Avula D, et al. *Screening, Brief Interventions, Referral to Treatment (SBIRT) for Illicit Drug and Alcohol Use at Multiple Healthcare Sites: Comparison at Intake and Six Months*. *Drug Alcohol Depend*. 2010;99(1-3):280-295.
33. Chychula NM, Sciamanna C. *Help Substance Abusers Attain and Sustain Abstinence*. *Nurse Pract*. 2002;27(11):30-47.
34. Institute of Medicine (IOM). [Crossing The Quality Chasm: A New Health System For The 21st Century](#). *IOM*. 2001.
35. American Psychiatric Association. [Substance-Related and Addictive Disorders](#). *APA*. 2013.
36. ASAM Board of Directors. [ASAM Public Policy Statement: Definition of Addiction](#). 2011.
37. SAMHSA. [Treatments for Substance Use Disorders](#). 2015.
38. USDHHS. [Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements](#). 2016.
39. Reuter N. *Personal Communication via E-Mail Re: Buprenorphine Waivered Physicians*. 2011.
40. SAMSHA. [National Survey of Substance Abuse Treatment Services \(N-SSATS\): 2014](#). March 2016.
41. Pade PA, Cardon KE, Hoffman RM, et al. *Prescription Opioid Abuse, Chronic Pain, and Primary Care: A Co-Occurring Disorders Clinic in the Chronic Disease Model*. *J Subst Abuse*

*Treat.* 2012;43(4):446-450.

42. Kahan M, Srivastava A, Ordean A, et al. *Buprenorphine: New Treatment of Opioid Addiction in Primary Care.* *Can Fam Physician.* 2011;57(3):281-289.

43. CADCA. [Comprehensive Addiction and Recovery Act \(CARA\)](http://www.cadca.org). *CADCA.org.* 2016.

44. Walden Greg. [Text - H.R.6 - 115th Congress \(2017-2018\): SUPPORT for Patients and Communities Act.](#) October 4, 2018.

45. Salsitz EA, Wunsch MJ. [PCSS-B Guidance on Drug Enforcement Administration Requirements for Prescribers and Dispensers of Buprenorphine and Buprenorphine/Naloxone.](#) 2010.

46. HHS. [HHS announces new actions to combat opioid epidemic.](#) *HHS.gov.* July 6, 2016.

47. Stanton A, McLoed C, Luckey B, et al. [SAMHSA/CSAT Evaluation of the Buprenorphine Waiver Program.](#) 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.

48. Lofwall MR, Walsh SL. *A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences from around the World.* *J Addict Med.* 2014;8(5):315-326.

49. Food and Drug Administration (FDA). [Physician Information: Answers to Frequently Asked Questions.](#) 2010.

Archived Material